Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7,503,646
-
Total 13F shares
-
15,707
-
Share change
-
+15,707
-
Total reported value
-
$105,865
-
Price per share
-
$6.74
-
Number of holders
-
6
-
Value change
-
+$105,865
-
Number of buys
-
6
Institutional Holders of Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) as of Q3 2024
As of 30 Sep 2024 Monopar Therapeutics - Common Stock, par value $0.001 per share (MNPR) had 6 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 15,707 shares of stock of the company.
Largest 6 holders included GEODE CAPITAL MANAGEMENT, LLC, NewEdge Advisors, LLC, UBS Group AG, WELLS FARGO & COMPANY/MN, Federation des caisses Desjardins du Quebec, and BANK OF AMERICA CORP /DE/.
This table shows 6 institutional shareholders of the security as of 30 Sep 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.